Author

Hee Yeon Kim

Seoul National University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 1 Neuroscience· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Approach:biophysical modeling· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Assay:proteomics· 1

Frequent Co-Authors

Daniel Youngjae Park· 2 shared Eun Hye ChoiD· 2 shared Sung Hyun KimiD· 2 shared Yong Tae KwoniD· 2 shared Chang Hoon JiiD· 1 shared Da-ha Park· 1 shared Gee Eun LeeiD· 1 shared Haneul ChoiiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

Daniel Youngjae Park

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

AUTOTAC-mediated targeted degradation of transthyretin aggregates ameliorates hereditary transthyretin amyloidosis

Hee Yeon Kim, Daniel Youngjae Park, Eun Hye Cho, Yeon Sung Son, Sung Hyun Kim, Ki Woon Sung, Helena Sofia Martins, Maria João Saraiva, Maria Rosário Almeida, Chang Hoon Ji, Yong Tae Kwon

This study identifies the N-degron pathway's role in lysosomal degradation of TTRV30M aggregates and demonstrates the therapeutic potential of AUTOTAC-based degraders for hATTR.

bioRxiv · Feb 24, 2026 · PreprintCell Biology

Targeted degradation of pathogenic TDP-43 proteins in amyotrophic lateral sclerosis using the AUTOTAC platform

Daniel Youngjae Park, Hee Yeon Kim, Eun Hye Cho, Haneul Choi, Da-ha Park, Gee Eun Lee, Sung Hyun Kim, Hye Yeon Kim, Young Ho Suh, Jin-A Lee, Yong Tae Kwon

This paper develops AUTOTAC degraders to target and degrade pathogenic TDP-43 aggregates in ALS, showing efficacy in mice and entering clinical trials.

bioRxiv · Aug 31, 2025 · PreprintNeuroscience